Identification of a Ribavirin‐resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy
Kung‐Chia Young, Karen L. Lindsay, Ki‐Jeong Lee, Wen‐Chun Liu, Jian‐Wen He, Susan L. Milstein, Michael M. C. Lai – 7 March 2007 – Ribavirin (RBV), a guanosine analogue, has been suggested to exert an antiviral action against hepatitis C virus (HCV) by causing lethal mutations and suppressing RNA polymerase in vitro, but the mechanism of its clinical therapeutic effects is currently unknown.